Health technology assessments and real-world evidence: tell us what you want, what you really, really want-Reference-Cited by-同舟云学术

Health technology assessments and real-world evidence: tell us what you want, what you really, really want

Published:2022-04 Issue:5 Volume:11 Page:297-299
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:J. Comp. Eff. Res.

Author:

Griesinger Frank¹,Cox Oliver²,Sammon Cormac³,Ramagopalan Sreeram V²,Popat Sanjay⁴

Affiliation:

1. Department of Medical Oncology, Pius-Hospital Oldenburg, Oldenburg, 26121, Germany

2. Global Access, F Hoffmann-La Roche, Basel, 4070, Switzerland

3. PHMR, London, NW1 8XY, UK

4. Lung Unit, Royal Marsden National Health Service Foundation Trust, Chelsea, London, SW3 6JJ, UK

Funder

F. Hoffmann-La Roche

Publisher

Becaris Publishing Limited

Subject

Health Policy

Link

https://becarispublishing.com/doi/pdf/10.2217/cer-2021-0296

Reference16 articles.

1. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries;Angelis A;Eur. J. Health Econ.,2018

2. Use of external comparators for health technology assessment submissions based on single-arm trials;Patel D;Value Health,2021

3. PBAC. Public Summary Document – alectinib – July 2017. www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2017-07/files/alectinib-psd-july-2017.pdf

4. CADTH. common drug review – ocrelizumab (2017). https://cadth.ca/ocrelizumab

5. CADTH. common drug review – tocilizumab (2018). www.cadth.ca/index.php/tocilizumab-3

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting the Population Health Economic Impact of Current and New Cancer Treatments for Colorectal Cancer: A Data-Driven Whole Disease Simulation Model for Predicting the Number of Patients with Colorectal Cancer by Stage and Treatment Line in Australia;Value in Health;2024-07

2. A tailored approach to horizon scanning for cancer medicines;Journal of Cancer Policy;2023-12